Spinifex Pharmaceuticals Pty Ltd.
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trial Designed to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy
Phase 2
Withdrawn
- Conditions
- Diabetic Neuropathies
- Interventions
- Drug: EMA401 600mgDrug: Placebo
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Spinifex Pharmaceuticals Pty Ltd
- Registration Number
- NCT02435199
Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN
Phase 2
Withdrawn
- Conditions
- Neuralgia, Postherpetic
- Interventions
- Drug: EMA401 200 mgDrug: EMA401 600 mgDrug: Placebo
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Spinifex Pharmaceuticals Pty Ltd
- Registration Number
- NCT02426411
© Copyright 2025. All Rights Reserved by MedPath